August 14, 2008, Yavne, Israel. CureTech, an Israeli biotechnology company specializing in development of innovative drugs for the treatment and control of cancer and Teva Pharmaceutical Industries have agreed to expand the scope of their original collaboration agreement from May 2006. Under the amended agreement CureTech will receive up to additional $10.5 million which will be utilized to support the ongoing Phase II study in diffuse large B cell lymphoma as well as a new Phase II study in previously untreated patients with metastatic colorectal cancer. All other terms and conditions of the original agreement have remained unchanged.

"We look forward to building on this success to advance CureTech’s CT-011 with Teva. We believe that this significant collaboration reflects the promise of CureTech’s CT-011 antibody in a range of therapeutic indications" said Dr. Michael Schickler, CEO of CureTech.

About CureTech

CureTech is a privately held biotechnology company operating out of Israel and focuses on the research, development and commercialization of novel, broad-spectrum, immune modulating products for the treatment and control of cancer. CureTech products offer an alternative approach to current biological cancer treatment by directly affecting specific functions of the immune system thus providing the safety inherent to antibody-based therapy and the ability to target a wide spectrum of malignancies. CureTech’s lead drug, CT-011, a humanized monoclonal antibody directed against PD-1, a B7 family-associated protein, has completed Phase I clinical testing.